| Date | Title | Description |
| 27.08.2024 | 3 High-Potential Biotech Stocks Under $10 The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could ... | The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCry... |
| 01.05.2024 | Tune Therapeutics to test vaccine-like epigenetics platform | Duke University spinout Tune Therapeutics is rehearsing the overture of its avant-garde therapeutic platform targeting chronic Hepatitis B Virus (HBV) that could also upend many more chronic disease treatments.
Tune, which is jointly based ... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 15.02.2024 | Molecular farming key to RTP startup's new sweetener | Elo Life Systems is a step closer to making the world a little sweeter.
The Research Triangle Park spinout from Precision BioSciences has raised an additional $20.5 million in capital, giving it a total of $45 million in funds raised to dat... |
| 10.01.2024 | Pontifax AgTech Achieves 2nd Exit as Precision Biosciences IPOs with $870m Valuation | - |
| 10.01.2024 | Precision BioSciences closes second deal for leading CART T candidate | Durham-based gene editing company Precision BioSciences has cut a second deal in six months involving its leading off-the-shelf CART T candidate, Azercabtagene Zapreleucel (azer-cel).
Precision said it has reached an agreement with TG Thera... |
| 27.02.2023 | Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes | Precision BioSciences, a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, announced a promotion and organizational changes within the Company’s Senior Leadership Team (S... |
| 10.12.2022 | Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hemato... | - Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel
- Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T D... |
| 22.01.2021 | BRIEF: Verdesian Life Sciences acquired by AEA Investors in exit for Paine Schwartz | Plant health and nutrition startup Verdesian Life Sciences has been acquired by New York-based AEA Investors, AFN has learned. Financial details of the deal were not disclosed. Verdesian was launched in 2012 by agrifood-focused private equi... |
| 27.09.2019 | How To Spot A Synthetic Biology Unicorn | Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta |
| 19.07.2019 | Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant | The field of off-the-shelf cell therapeutics is growing, with the promise of quicker, cheaper, and easier to manufacture therapies than the first generation of autologous CAR-Ts that impressed with their potency but fe... |
| 28.03.2019 | Pontifax AgTech Achieves 2nd Exit as Precision Biosciences IPOs with $870m Valuation | Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO, valuing the company at $870 million.
The IPO will achieve an exit for growth stage agrifood tech investo... |
| 27.03.2019 | Precision BioSciences Prices IPO at $16 Per Share, Raises $126.4M | A genome editing company based in the Research Triangle Park raised $126.4 million in an initial public offering on Wednesday.
Durham-based Precision BioSciences Inc. sold 7.9 million shares of stock at a public offering price of $16 per sh... |
| 18.03.2019 | Early stage cancer biotech Precision BioSciences sets terms for $126 million IPO | - |
| 03.02.2019 | Coastal startups don’t have a monopoly on raising big at early-stage | Jason Rowley Contributor
Jason Rowley is a venture capital and technology reporter for Crunchbase News.
More posts by this contributor
Ride-hailing, bike and scooter companies probably raised less money than you thought
To get big faster, y... |
| 01.02.2019 | Coastal Startups Don’t Have A Monopoly On Raising Big At Early Stage | 25 Shares Email Facebook Twitter LinkedIn
Early-stage startups throughout much of the U.S. are able to raise larger sums today than any other point in at least a decade, and there are more early-stage rounds than ever, both in North America... |
| 28.06.2018 | Term Sheet — Thursday, June 28 | LYFTED
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here are some additional notes:
• In total, Lyft has raised $5.1 billion in funding. Lyft’s investors include AllianceBernstein, Baillie... |
| 28.06.2018 | Precision BioSciences Raises $110M in Series B |
DURHAM, NC, Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing.
>> Click here for more funding data on Precision BioSciences
>> To export Precision BioSciences funding data to PDF... |
| 28.06.2018 | Precision BioScience Raises $110M Series B | Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was led by ArrowMark Partners and was joined b... |
| 27.06.2018 | IPO bound? Crossovers join big syndicate backing Precision BioSciences’ $110M gene editing round | With a base in Durham, NC, Precision BioSciences has managed to stay off the gene-editing radar that has spotlighted some of the leading players in the field. But that doesn’t mean that investors have been ignoring the work.
Mat... |
| 26.06.2018 | Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs | DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was... |
| 26.06.2018 | Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs | - |
| 26.06.2018 | Precision BioSciences Raises $110M in Series B Funding | Precision BioSciences, a Durham, NC-based biotechnology company, closed a $110M Series B financing.
The round was led by ArrowMark Partners with participation from new investors Franklin Templeton Investments, Cowen Healthcare Investments, ... |
| 10.05.2018 | Should You Be Using CRISPR for Your Ag Business? | *Updated reference to Pairwise with correction regarding agreement with Monsanto*
Editor’s Note: Vonnie Estes was the 2017 recipient of Rosalind Franklin award for leadership in Biotechnology. She is an agtech innovation consultant with a p... |
| 09.06.2016 | How Big Data is Disrupting Agriculture from Biological Discovery to Farming Practices | Editor’s Note: Vonnie Estes is an agtech consultant with a particular focus on building biotech-focused startups. She has worked in business development roles at three of the big 6 — Monsanto, Syngenta, and DuPont — and is a known face in t... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now... |
| 12.05.2015 | Precision BioSciences Raises $25.6M to Expand Genome Editing Platform | Genome editing-based company, Precision BioSciences announced it has closed $25.6 million Series A financing led by venBio. The Research Triangle Park, North Carolina-based company’s oversubscribed round was also joined by Fidelity Bioscien... |
| 11.05.2015 | Precision BioSciences Closes $25.6M Series A Financing | Precision BioSciences, a Research Triangle Park, N.C.-based genome editing company, closed a $25.6m Series A financing.
The round was led by venBio with participation from Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage Univers... |
| 11.05.2015 | Precision BioSciences Lands $25.6M Series A |
RESEARCH TRIANGLE PARK, NC, Genome editing company, today announced the closing of a $25.6 million Series A financing led by venBio.
>> Click here for more funding data on Precision BioSciences
>> To export Precision BioScie... |
| 30.01.2012 | DNA technology from Precision BioSciences gets USPTO allowance | Precision’s technology is called Directed Nuclease Editor technology, or DNE. The genomics technology allows scientists to insert, remove, modify or regulate genes for applications in plant science and human biotechnology. The company’s ‘60... |
| 23.01.2012 | Genome engineering firm Precision BioSciences gets patent victory | The Precision and Cellectis patent dispute dates back several years. In 2008, Cellectis filed claims on two in-licensed patents, claims that the patent office rejected. For the latest patent office decision, Cellectis does have the opportun... |
| 19.01.2012 | Precision BioSciences splits plant unit from human genomics research | “Moving forward, this new business structure will enable our companies to focus on their respective markets and will provide both with new strategic and financial options as they grow and develop into the future,” he said.
Precision BioScie... |
| - | Precision BioSciences splits plant unit from human genomics research | North Carolina biotechnology company Precision BioSciences is splitting into two divisions, one that will focus on humans and another that will focus on plant biotechnology.
With the change, the Durham company is creating Precision PlantSci... |
| - | DNA technology from Precision BioSciences gets USPTO allowance | North Carolina biotechnology firm Precision BioSciences is on its way to strengthening patent protection for its genome engineering technology.
The U.S. Patent and Trademark Office has issued a “notice of allowance” for a Precision patent a... |
| - | Pontifax AgTech Achieves 2nd Exit as Precision Biosciences IPOs with $870m Valuation | |
| - | Genome engineering firm Precision BioSciences gets patent victory | North Carolina biotechnology company Precision BioSciences has secured a patent victory for its genome engineering technology.
The U.S. Patent and Trademark Office has rejected claims from French company Cellectis that alleges that Precisio... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p... |
| - | Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs | DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was... |
